Skip Navigation LinksHome > June 2009 - Volume 337 - Issue 6 > Severe Pulmonary Hemorrhage in Patients With End-Stage Renal...
American Journal of the Medical Sciences:
doi: 10.1097/MAJ.0b013e3181928d24
Clinical Investigation

Severe Pulmonary Hemorrhage in Patients With End-Stage Renal Disease in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.

Chen, Min MD; Zhao, Ming-Hui MD, PhD

Collapse Box

Abstract

Background: It has been reported that after patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) progress to end-stage renal disease (ESRD), they are less likely to experience relapse of vasculitis. However, we encountered a few patients with ESRD suffering severe pulmonary hemorrhage caused by relapse of AAV. The current study presents our observation on these patients.

Methods: Of 198 consecutive patients with AAV with follow-up data in our center, 66 progressed to ESRD during follow-up. Clinical and laboratory data were collected and retrospectively analyzed.

Results: Among the 66 patients with ESRD, 5 experienced severe pulmonary hemorrhage. They had positive serum perinuclear ANCA and myeloperoxidase ANCA and were diagnosed as microscopic polyangiitis. All 5 patients achieved remission after initial induction therapy. The average duration of follow-up was 47.0 (range 8.0-98.0) months. After progressing to ESRD and starting hemodialysis, these patients experienced severe pulmonary hemorrhage within 9.0 (range 2.0-23.0) months. After immunosuppressive therapy, pulmonary hemorrhage ceased in 4 patients, and the other died of respiratory failure.

Conclusions: Severe pulmonary hemorrhage can occur in ESRD patients with AAV. Disease activity and relapses of AAV should be monitored even after patients progress to ESRD.

© Copyright 2009 Southern Society for Clinical Investigation

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.